Press Releases

 
Press Releases
  Date Title and Summary View
Mar 1, 2017
AMES, Iowa, March 01, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology therapies to patients with cancer, today reported that two abstracts on the company's indoximod program will be presented at the American Association for Cancer Research (AACR) 2017 Annua...
Feb 28, 2017
AMES, Iowa, Feb. 28, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology therapies to patients with cancer, today reported consolidated financial results for the fourth quarter and year ended 2016, as well as progress in its clinical development programs. NewLi...
Feb 20, 2017
AMES, Iowa, Feb. 20, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), today reported that it will release its fourth quarter and year end 2016 financial results on Tuesday, February 28, 2017.  The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results and to give an update on clinical and bu...
Feb 13, 2017
AMES, Iowa, Feb. 13, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology therapies to patients with cancer, today announced that it will participate in the 2017 SunTrust Robinson Humphrey Orphan Drug Day on February 14 in New York City. About NewLink Genet...
Nov 9, 2016
AMES, Iowa, Nov. 09, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology therapies to patients with cancer, today announced that it will participate in the Global Mizuho Investor Conference on November 14, the Stifel 2016 Healthcare Conference on November 15 an...
Nov 1, 2016
AMES, Iowa, Nov. 01, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology therapies to patients with cancer, today reported consolidated financial results for the third quarter of 2016 and progress in its clinical and pipeline development programs. "We cont...
Oct 25, 2016
Two Distinct IDO Pathway Inhibitors in Clinical Development Indoximod, Exclusive to NewLink GeneticsGDC-0919 in Partnership with Genentech, a Member of the Roche Group AMES, Iowa & NEW YORK, Oct. 25, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology the...
Oct 24, 2016
AMES, Iowa, Oct. 24, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), today reported that it will release its third quarter 2016 financial results on Tuesday, November 1, 2016. The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results and to give an update on clinical and business developme...
Oct 20, 2016
AMES, Iowa, Oct. 20, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will webcast its Analyst and Investor Day being held on Tuesday, October 25 at the Convene Meeting Center in New York City. The Analyst and Investor Day will be webcast live and a link can be accessed at edge.media-server.com/m/p...
Oct 4, 2016
AMES, Iowa, Oct. 04, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), announced today that the Biomedical Advanced Research and Development Authority (BARDA) of the United States Department of Health and Human Services (HHS) has issued a $24.8 million contract to a subsidiary of NewLink Genetics to support the advanced develop...
Page:
1
... NextLast
= add release to Briefcase